Most pharmaceutical companies get their drugs manufactured by other smaller companies. For any violations of drug regulations, the Food and Drug Administration (FDA) only took action on the drug producing company. However now, the companies marketing medicines in India will also be liable as the manufacturers i.e. the third-party companies. The Drugs Technical Advisory Board (DTAB) gave out this information recently.
According to persons aware of the development, the move is expected to check quality lapses in medicines consumed by patients in India and also enable the marketing companies to directly monitor the standard of these medicines. Arjun Khadtar, Joint Commissioner, Brihanmumbai (Drug), FDA confirmed this with Mumbai Live.
The Third-party pharmaceutical industry has been experiencing a growth for the majority of drug production off late, as it cuts down on the cost of production and significantly benefits bigger companies. The Third-party companies, however, are not being able to maintain the quality of the drugs. Under this circumstance, only the medicine marketing companies were scrutinized. Hence, the third-party companies being the main culprit in the scene were overlooked and not held responsible for spurious medicines.
The Central Government's Drugs Technical Advisory Board has made some recommendations including taking action against the Third Party companies which await the approval of the Central Government. Once these recommendations get the green light, significant provisions will be made in the Drugs and Cosmetic Act following a law enforcement.
Share
Tweet
